# A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

> **NCT04395677** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nuvation Bio Inc.** · enrollment: 173 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AB-106

## Key facts

- **NCT ID:** NCT04395677
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-07
- **Primary completion:** 2024-06-07
- **Final completion:** 2027-06
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04395677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04395677, "A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04395677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*